Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015-2020)

J Small Anim Pract. 2021 Oct;62(10):881-885. doi: 10.1111/jsap.13387. Epub 2021 Jun 16.


Objective: To determine the median survival time (MST) of dogs with nasal carcinoma treated with toceranib phosphate.

Material and methods: The databases of four Spanish referral hospitals were retrospectively searched for dogs with a diagnosis of nasal tumours presented between January 2015 and October 2020. Dogs treated with radiotherapy or other chemotherapies prior toceranib were excluded.

Results: Twenty-three dogs with a confirmed nasal carcinoma treated with toceranib phosphate and with a CT scan for initial staging according to Adams Modified Staging System were included. Nine dogs had a stage III nasal carcinoma whereas 14 dogs had a stage IV nasal carcinoma. No dog had stages I and II nasal carcinoma. The median overall survival time was 139 days. The difference between the MST between dogs with stages III and IV was not statistically significant [P = 0.6, 140 days for stage III (range 46-401) vs 120 days for stage IV (range 23-600)]. Overall, dogs with epistaxis achieved a longer median survival (166 days) than dogs without epistaxis (83 days). Toceranib phosphate was generally well tolerated. Most dogs had an initial clinical benefit followed by progressive disease.

Significance: This is the first study to report the MST in dogs with stages III and IV nasal carcinoma treated with toceranib phosphate. This retrospective study showed that toceranib phosphate decreases the clinical signs associated with nasal carcinomas.

MeSH terms

  • Animals
  • Antineoplastic Agents* / therapeutic use
  • Carcinoma* / veterinary
  • Dog Diseases* / drug therapy
  • Dogs
  • Indoles
  • Nose Neoplasms* / drug therapy
  • Nose Neoplasms* / veterinary
  • Pyrroles / therapeutic use
  • Retrospective Studies


  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • toceranib phosphate